RU95119937A - METHOD FOR ESTIMATING EFFECTIVENESS OF THERAPY - Google Patents

METHOD FOR ESTIMATING EFFECTIVENESS OF THERAPY

Info

Publication number
RU95119937A
RU95119937A RU95119937/14A RU95119937A RU95119937A RU 95119937 A RU95119937 A RU 95119937A RU 95119937/14 A RU95119937/14 A RU 95119937/14A RU 95119937 A RU95119937 A RU 95119937A RU 95119937 A RU95119937 A RU 95119937A
Authority
RU
Russia
Prior art keywords
therapy
antipyrine
average molecular
effectiveness
albumin
Prior art date
Application number
RU95119937/14A
Other languages
Russian (ru)
Inventor
Э.Э. Кузнецова
И.Б. Рудых
В.Г. Леонтьева
Т.Е. Курильская
А.А. Рунович
Original Assignee
Научно-исследовательский институт хирургии Восточно-сибирского научного центра СО РАМН
Filing date
Publication date
Application filed by Научно-исследовательский институт хирургии Восточно-сибирского научного центра СО РАМН filed Critical Научно-исследовательский институт хирургии Восточно-сибирского научного центра СО РАМН
Publication of RU95119937A publication Critical patent/RU95119937A/en

Links

Claims (1)

Способ оценки эффективности эфферентной терапии, включающий проведение перфузии крови через массообменник с последующим определением концентрации веществ средней молекулярной массы в сыворотке крови, отличающийся тем, что до и после проведения эфферентной терапии в плазме крови определяют содержание среднемолекулярного пептида, эффективную концентрацию альбумина, время полувыведения и клиренс антипирина и при снижении содержания среднемолекулрного пептида не менее чем на 30%, увеличении эффективной концентрации альбумина на 8 - 10%, времени полувыведения антипирина не менее чем на 30% и увеличении клиренса антипирина не менее чем на 50% эфферентную терапию оценивают как эффективную.A method for evaluating the effectiveness of efferent therapy, including perfusion of blood through a mass exchanger with subsequent determination of the concentration of substances of average molecular weight in blood serum, characterized in that before and after conducting efferent therapy in plasma, the content of the average molecular peptide, the effective concentration of albumin, half-life and clearance are determined antipyrine and with a decrease in the content of the average molecular peptide by at least 30%, an increase in the effective concentration of albumin by 8 - 10%, the half-life of antipyrine is not less than 30% and the increase in clearance of antipyrine is not less than 50%, the efferent therapy is evaluated as effective.
RU95119937/14A 1995-11-22 METHOD FOR ESTIMATING EFFECTIVENESS OF THERAPY RU95119937A (en)

Publications (1)

Publication Number Publication Date
RU95119937A true RU95119937A (en) 1997-10-20

Family

ID=

Similar Documents

Publication Publication Date Title
DE3685625D1 (en) ANTIBODY COMPLEXES OF HAPTEN-MODIFIED DIAGNOSTIC OR THERAPEUTIC AGENTS.
RU95119937A (en) METHOD FOR ESTIMATING EFFECTIVENESS OF THERAPY
Prasad et al. The base binding property of the serum proteins with respect to magnesium
ATE20568T1 (en) FLAVORING AGENTS AS A SUBSTITUTE FOR SODIUM CHLORIDE.
Adachi et al. Selective removal of immunoglobulin E from rat blood by membrane-immobilized antibody
PT1039297E (en) REAGENT FOR THE DETERMINATION OF LEUKOCYTES AND THE QUANTIFICATION OF HEMOGLOBIN IN A SAMPLE OF BLOOD
Spears et al. Influence of clozapine on water dysregulation.
RU2000110089A (en) METHOD FOR DIAGNOSTIC OF MUCOPOLYSACCHARIDOSES
RU97115180A (en) METHOD FOR DETERMINING TOXICITY OF ACTION OF HEAVY METALS ON THE ORGANISM
RU96120708A (en) METHOD FOR DETERMINING INDICATIONS FOR CARRYING OUT EFFECTIVE THERAPY
RU95108344A (en) METHOD FOR ESTIMATING EFFECTIVENESS OF TREATMENT OF ISCHEMIC HEART DISEASE
Marino et al. Pharmacokinetics and biochemical effects of hepapoietin in patients with chronic liver disease
RU98119668A (en) METHOD FOR IMPROVING RESISTANCE TO HEMOLYSIS OF ERYTHROCYTES AND RESTORING THEIR DAMAGED FORM
SE9401975D0 (en) The use of sialic acid determinations
RU93012781A (en) METHOD FOR DIAGNOSTIC OF Adenomyosis
FUJITA et al. Age difference in response of erythrocyte δ-aminolevulinic acid dehydratase amount to lead administration in rats
RU96106234A (en) METHOD FOR DETERMINING IMMUNOCYTOTHERAPY EFFICIENCY IN PATIENTS WITH OPH HESTOSIS
RU96118343A (en) METHOD FOR DIAGNOSTIC OF ATROPHIC ENDOBRONCHITIS
RU96114147A (en) METHOD FOR IDENTIFYING SMALL HEPATIC INSUFFICIENCY
Taylor et al. Enzymatic measurement of sweat sodium and chloride
KR870700020A (en) Protein absorption enhancer
RU96108150A (en) METHOD FOR DETERMINING THE BLOOD TOXICITY OF FISH
UA30407A (en) Method for diagnosing heart failure
Razumovskij et al. Determination of the Solubility and Diffusion Coefficient of Water in Aliphatic Polyamides at Different Humidity
Molenda Physiological values of urine delta-aminolevulinic acid in subjects from urban population.